Transpire is lined up to copy 1 of the blockbuster drugs on this tracker, which earned $3.9B combined in 2025.
| Drug | Brand owner | Copy | US LOE | Transpire's stage | 2025 brand sales |
|---|---|---|---|---|---|
| Trelegy | GSK | Generic | 2027 | Filed with the FDA; in litigation, sued Mar 2026. Filed for 100 mcg (Jan 2026) and 200 mcg (May 2026); trial in the first case set for Feb 2028 | ≈$3.9B |
Each drug page lists sources for these entries. Brand sales show the size of the market, not Transpire's share of it.